Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at a critical juncture as it navigates through a challenging biotech ...

The Bay Area-based biotech unveiled its ambition earlier this month to go public, and Maze has now stuck some numbers to this plan. The aim is to sell 7.8 million shares priced between $15 and $17 ...

Only one traditional preclinical biotech—Metagenomi—went public last year, compared to around a quarter of the biotechs that IPOed in 2020 and 2021, according to Surti. About two-thirds of the ...

This research is detailed in a study published in Nature Biotechnology, entitled “Uniform volumetric single-cell processing for organ-scale molecular phenotyping.” The work demonstrates a ...

The synthetic chromosome includes features that enable researchers to generate genetic diversity on demand, accelerating the development of yeasts with enhanced capabilities for biotechnology ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...